medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Authors:
Jonguk Kim (Bundang Seoul National University Hospital)
Jun Yup Kim (Seoul National University Bundang Hospital, Seoul National University College of Medicine)
Jihoon Kang (Seoul National University Bundang Hospital)
Beom Joon Kim (Seoul National University Bundang Hospital)
Moon-Ku Han (Seoul National University College of Medicine, Seoul National University Bundang Hospital)
Jeong-Yoon Lee (Seoul National University Bundang Hospital)
Tai Hwan Park (Seoul Medical Center)
Ji Sung Lee (Asan Medical Center)
Keon-Joo Lee (Korea University Guro Hospital)
Joon-Tae Kim (Chonnam National University Hospital)
Kang-Ho Choi (Chonnam National University Hospital)
Jong-Moo Park (Uijeongbu Eulji Medical Center, Eulji University)
Kyusik Kang (Nowon Eulji Medical Center, Eulji University)
Soo-Joo Lee (Eulji University Hospital)
Jae Guk Kim (Daejeon Eulji Medical Center, Eulji University School of Medicine)
Jae-Kwan Cha (Dong-A University Hospital)
Dae-Hyun Kim (Dong-A University Hospital)
Kyungbok Lee (Soonchunhyang University College of Medicine)
Jun Lee (Yeungnam University Hospital)
Keun-Sik Hong (Ilsan Paik Hospital, Inje University)
Yong-Jin Cho (Ilsan Paik Hospital, Inje University)
Hong-Kyun Park (Inje University Ilsan Paik Hospital)
Byung-Chul Lee (Hallym University Sacred Heart Hospital, Hallym University College of Medicine)
Kyung-Ho Yu (Hallym University Sacred Heart Hospital)
Mi Sun Oh (Hallym University Sacred Heart Hospital, University College of Medicine)
Dong-Eog Kim (Dongguk University)
Wi-Sun Ryu (JLK Inc.)
Jay Chol Choi (Jeju National University)
Jee-Hyun Kwon (Ulsan university college of medicine)
Wook-Joo Kim (Ulsan University Hospital, University of Ulsan College of Medicine)
Dong-Ick Shin (Chungbuk National University Hospital)
Kyu Sun Yum (Chungbuk National University Hospital)
Sung-Il Sohn (Dongsan Hospital, Keimyung University School of Medicine)
Jeong-Ho Hong (Keimyung University Dongsan Hospital)
Sang-Hwa Lee (Chuncheon Sacred Heart Hospital, Hallym University College of Medicine)
Juneyoung Lee (College of Medicine, Korea University)
Philip B Gorelick (Davee Department of Neurology, Northwestern University Feinberg School of Medicine)
Hee-Joon Bae (Seoul National University Bundang Hospital)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Improvement in Delivery of Ischemic Stroke Treatments but Stagnation of Clinical Outcomes in Young Adults in South Korea

Jonguk Kim, MD[1], Jun Yup Kim, MD[1], Jihoon Kang MD, PhD[1], Beom Joon Kim, MD, PhD[1], Moon-Ku Han, MD, PhD[1], Jeong-Yoon Lee, MD[1], Tai Hwan Park, MD, PhD[2], Ji Sung Lee, PhD[3], Keon-Joo Lee, MD[4], Joon-Tae Kim, MD, PhD[5], Kang-Ho Choi, MD, PhD[5], Jong-Moo Park, MD, PhD[6], Kyusik Kang, MD, PhD[7], Soo Joo Lee, MD, PhD[8], Jae Guk Kim, MD[8], Jae-Kwan Cha, MD, PhD[9], Dae-Hyun Kim, MD, PhD[9], Kyung Bok Lee, MD, PhD[10], Jun Lee, MD, PhD[11], Keun-Sik Hong, MD, PhD[12], Yong-Jin Cho, MD, PhD[12], Hong-Kyun Park, MD, PhD[12], Byung-Chul Lee, MD, PhD[13], Kyung-Ho Yu, MD, PhD[13], Mi-Sun Oh, MD[13], Dong-Eog Kim, MD, PhD[14], Wi-Sun Ryu, MD, PhD[14], Jay Chol Choi, MD, PhD[15], Jee-Hyun Kwon, MD, PhD[16], Wook-Joo Kim, MD[16], Dong-Ick Shin, MD, PhD[17], Kyu Sun Yum, MD[17], Sung Il Sohn, MD, PhD[18], Jeong-ho Hong, MD, PhD[18], Sang-Hwa Lee, MD, PhD[19], Juneyoung Lee, PhD[20], Philip B. Gorelick, MD MPH[21] and Hee-Joon Bae, MD, PhD[1]

[1]Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea

[2]Department of Neurology, Seoul Medical Center, Seoul, Korea

[3]Clinical Research Center, Asan Medical Center, Seoul, Korea

[4]Department of Neurology, Korea University Guro Hospital, Seoul, Korea

[5]Department of Neurology, Chonnam National University Hospital, Gwangju, Korea

[6]Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Korea

[7]Department of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

[8]Department of Neurology, Eulji University Hospital, Daejeon, Korea

[9]Department of Neurology, Dong-A University Hospital, Busan, Korea

[10]Department of Neurology, Soonchunhyang University Hospital, Seoul, Korea

[11]Department of Neurology, Yeungnam University Medical Center, Daegu, Korea

[12]Department of Neurology, Inje University Ilsan Paik Hospital, Goyang, Korea

[13]Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea

[14]Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea

[15]Department of Neurology, Jeju National University Hospital, Jeju, Korea

[16]Department of Neurology, Ulsan University Hospital, Ulsan, Korea

[17]Department of Neurology, Chungbuk National University & Hospital, Cheongju, Korea

[18]Department of Neurology, Keimyung University Dongsan Hospital, Daegu, Korea

[19]Department of Neurology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea

[20]Department of Biostatistics, Korea University, Seoul, Korea

[21]Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Corresponding author: Hee-Joon Bae, braindocbae@gmail.com, 82, Gumi-ro 173, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Korea

Short title: Secular Trends in Young Adult Stroke

Word count: 5957

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Background

There is limited information on the delivery of acute stroke therapies and secondary preventive measures and clinical outcomes over time in young adults with acute ischemic stroke (AIS). This study investigated whether advances in these treatments improved outcomes in this population.

Methods

Using a prospective multicenter stroke registry in Korea, young adults (aged 18–50 years) with AIS hospitalized between 2008 and 2019 were identified. The observation period was divided into four epochs: 2008–2010, 2011–2013, 2014–2016, and 2017–2019. Secular trends for patient characteristics, treatments, and outcomes were analyzed.

Results

A total of 7,050 eligible patients (mean age 43.1; men 71.9%) were registered. The mean age decreased from 43.6 to 42.9 years (P_{trend}=0.01). Current smoking decreased, whereas obesity increased. Other risk factors remained unchanged. Intravenous thrombolysis and mechanical thrombectomy rates increased over time from 2008–2010 to 2017–2019 (9.5% to 13.8% and 3.2% to 9.2%, respectively; P_{trend}'s<0.01). Door-to-needle time improved (P_{trend}<0.001), but onset-to-door and door-to-puncture time remained constant. Secondary prevention including dual antiplatelets for noncardioembolic minor stroke (26.7% to 47.0%), direct oral anticoagulants for atrial fibrillation (0.0% to 56.2%), and statins for large artery atherosclerosis (76.1% to 95.3%) increased (P_{trend}'s<0.01). Outcome data were available since 2011. One-year mortality (2.5% in 2011–2013 and 2.3% in 2017–2019) and 3-month

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

modified Rankin scale scores 0–1 (68.3% to 69.1%) and 0–2 (87.6% to 86.2%) remained unchanged. One-year stroke recurrence rate increased (4.1% to 5.5%, P_{trend}=0.04), but was not significant after adjusting for warfarin use.

Conclusion

Improvements in the delivery of acute stroke treatments did not necessarily lead to better outcomes in young adults with AIS over the past decade, indicating a need for further improvement.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

Young adults, commonly defined as individuals aged 18 to 50, constitute 10–15% of the acute ischemic stroke (AIS) population.[1] While the incidence of ischemic stroke has declined in the general population, it has risen among young adults.[2] Moreover, healthcare expenses for young adults with stroke are significant as they are 1.6 times greater than those for older patients.[3] Improving outcomes in young adults with stroke is particularly important, given the potential socioeconomic implications associated with increased life expectancy.

Over the past 15 years, there have been significant advancements in acute reperfusion therapy and secondary preventive treatment for ischemic stroke. Intravenous thrombolysis (IVT) beyond 3 hours and mechanical thrombectomy (MT) for large artery occlusion have become the standard of care.[4,5] The CHANCE trial demonstrated the efficacy of dual antiplatelet therapy (DAPT) for noncardioembolic minor strokes.[6] Direct oral anticoagulants (DOACs) have replaced warfarin for atrial fibrillation.[7] With the increasing use of reperfusion therapies and secondary preventative treatments, real-world data have shown improvements in clinical outcomes for the general stroke population.[8–10]

However, limited data exist on whether these advanced treatments were applied to young patients with stroke and whether their outcomes improved accordingly. Previous studies about outcomes in young patients were limited by cross-sectional rather than longitudinal designs,[11,12] small sample sizes,[13,14] or were conducted before 2010, when many advanced treatments had yet to be introduced.[11,14,15] This study aims to fill the knowledge gap on secular trends in treatments and outcomes in young adults with AIS using a multicenter stroke registry in South Korea.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Methods

Study Population

This retrospective analysis was based on data from a prospective, multicenter stroke registry - the Clinical Research Collaboration for Stroke in Korea-National Institutes of Health (CRCS-K-NIH) registry. The CRCS-K-NIH is a web-based registry implemented in 2008 to register patients with acute stroke or transient ischemic attack admitted to the 17 participating stroke centers in South Korea. Detailed information on the CRCS-K-NIH registry is provided elsewhere.[16] We included patients who were aged 18–50 years at presentation, had AIS defined as having ischemic symptoms for more than 24 h or a relevant ischemic lesion on diffusion-weighted MRI, arrived within seven days from when patients recognized stroke symptoms (first abnormal time [FAT]), and were hospitalized between April 2008 and December 2019.

Ethics Statement

Ethical approval for using the CRCS-K-NIH registry database was obtained from the institutional review boards of all participating hospitals (B-2112-728-102). A waiver of informed consent was granted because of the use of de-identified data and minimal risk to participants.

Data Collection

Information on demographics, risk factors, blood pressure, laboratory data, premorbid disability (modified Rankin scale [mRS]), initial National Institute of Health Stroke Scale (NIHSS), stroke subtype according to the Trial of Org 10172 in Acute Stroke

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Treatment (TOAST) criteria with some modifications,[17] FAT, last known well time (LKW), diagnostic evaluations, reperfusion therapies, door-to-needle time (DNT), door-to-puncture time (DPT), and discharge medications were obtained from the registry database. Risk factors were dichotomized into two categories: "newly diagnosed" and "previously known or aware," and the "aware" category was further divided into "on medication" and "not on medication" based on the treatment status.

As part of a program aimed at monitoring and improving the quality of stroke care and outcomes, functional outcomes and occurrence of clinical events, including recurrent stroke and death, were prospectively captured at discharge, 3 months, and 1 year after the index stroke through a structured telephone interview conducted by experienced nurse coordinators or a direct interview by treating physicians at outpatient clinics according to predetermined protocols. Functional outcomes were evaluated using the mRS and were dichotomized into mRS scores of 0–1 vs. 2–6 and 0–2 vs. 3–6 or were treated as an ordinal variable. Operational definitions of all variables are listed in Table S1.

Statistics

We described demographics, risk factors, stroke characteristics, diagnostic evaluations, and treatments across four epochs: 2008–2010, 2011–2013, 2014–2016, and 2017–2019. For trend analyses, the ANOVA linear contrast test was applied to continuous, and the Cochrane–Armitage test was applied to categorical variables. The Mantel–Haenszel chi-square test was used to treat the 3-month mRS as an ordinal variable. The Kaplan–Meier product limit method was implemented to estimate mortality and cumulative incidence of recurrent strokes, which were subsequently compared across the epochs using a log-rank linear contrast test. Among the 63 variables used in the study, 20 variables were found to

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

have one or more missing values, resulting in an overall missing rate of 0.49%. These missing values were removed pairwise during the tabulation and analysis.

Stroke outcomes were analyzed with and without adjustment. Variables for adjustment were predetermined as follows: 1) sex, age, and initial NIHSS score for 3-month mRS score and mortality, and 2) sex, age, stroke risk factors, and stroke subtypes for recurrent stroke. For trend analyses in multivariable models, a linear contrast test was applied to binary outcomes in logistic regression models, to survival outcomes in Cox proportional hazard models, and to the whole scale of 3-month mRS scores in an ordinal logistic regression model. Secular trends were analyzed according to age (18–30, 31–40, and 41–50 years) and sex subgroups and presented if needed. Furthermore, secular trends in treatments and outcomes were demonstrated in subgroups of potential contributing factors.

A two-tailed *p*-value of <0.05 was considered statistically significant. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R software version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

Data Availability

The data used in this study may be made available upon request to the corresponding author.

Results

Demographics, Risk Factors, and Subtypes of Ischemic Stroke (Table 1)

Of 70,567 patients (age 68.3±13.0 years; men 58.5%) registered with AIS between 2008 and 2019, 7,050 participants aged 18–50 (10.0%) were selected. Over the 12 years, the proportion of men slightly decreased from 74% to 71% (p_{trend}=0.10), but it remained more

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

than twice that of women. The mean age decreased in both sexes, but this was statistically significant only in women. The decrease in mean age in women was attributable to an increase in the proportion of women aged 18–30 (Figure 1).

Regarding traditional vascular risk factors, we observed significant trends in smoking and obesity. Current smoking decreased by 13.5% in men but increased by 2.5% in women. The increase in obesity (body mass index ≥30 kg/m^2) was more than two times greater in men and was less evident in women. However, no significant trends were observed regarding hypertension, diabetes mellitus, and hyperlipidemia. Awareness and treatment rates of hypertension, diabetes, and hyperlipidemia before the index stroke remained unchanged except for increased awareness of hyperlipidemia.

For ischemic stroke subtypes, large artery atherothrombosis (LAA) was the most common, followed by small vessel occlusion (SVO) or undetermined etiology (UDE; depending on the epoch). Notably, other determined etiology (ODE) increased by 9.0%, but LAA, SVO, and cardioembolic stroke (CES) decreased by 2.5%, 5.1%, and 4.3%, respectively. Among ODEs, arterial dissection was the most common, followed by intrinsic diseases of the arterial wall, such as Moyamoya disease and fibromuscular dysplasia (Table S2). Arterial dissection significantly increased in both men and women by 4.7% and 5.1%, respectively. The proportion of UDEs remained unchanged throughout the study period.

Clinical Presentation and Treatments (Tables 2)

Over the 12 years, the onset-to-door time (ODT) remained unchanged; the median FAT-to-door ranged between 8.0 and 9.4h, and the median LKW-to-door between 11.1 and 12.5h. Overall, the proportion of patients hospitalized within 3.5h from LKW was 27.5%. However, initial stroke severity decreased significantly, with a reduction in the mean NIHSS

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

score and the proportion of severe strokes (NIHSS score 16–42) by 0.8 points and 1.9%, respectively.

The IVT rate increased by 3.8% between the first two epochs but plateaued afterward. The DNT followed a similar pattern. The overall increase in IVT rate may be attributed to the rise in IVT rate in patients arriving between 3.0 and 4.5 hours from the LKW (from 5.8% in 2008–2010 to 21.1% in 2017–2019) and in those with severe stroke (from 27.9% to 47.3%; Tables S3 and S4). However, it should be noted that the IVT rate remained low in patients arriving after 4.5 h and in those with mild stroke (2.4% and 5.0% in 2017–2019, respectively).

Over the 12 years, the MT rate almost tripled (from 3.2% to 9.2%), but the DPT did not improve. The increase in MT rate was evident in patients arriving within 6 hours or between 6 and 12 hours and in those with moderate (NIHSS score 5–15) or severe stroke (Tables S3 and S4). However, it should be noted that the MT rates in patients arriving after 12 hours and in those with mild stroke remained low (2.1% and 1.9% in 2017–2019, respectively).

Regarding secondary preventive treatments, the overall use of DAPT and DAPT in mild noncardioembolic stroke increased by 20.3% and 22.2%, respectively. The overall use of statins and the use of statins in LAA also increased by 19.7% and 19.2%, respectively. However, the overall use of anticoagulants and anticoagulants in atrial fibrillation decreased by 7.2% and 6.4%, respectively. Among types of anticoagulants in patients with atrial fibrillation, DOAC surpassed warfarin in the last epoch. DOAC use in patients with atrial fibrillation began to be reimbursed by the Korean government in mid-2015. It should be mentioned that in ODEs, the use of anticoagulants decreased by 29.7%, and the use of DAPT increased by 20.3% (Table S5).

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The clinical presentation and treatment trends did not change noticeably in subgroup analyses according to age group (not presented here) and sex (Table S6).

Clinical Outcomes (Table 3)

Outcome data were available in 6,057 patients registered since 2011. The median follow-up was 367 days, with 94.6% (n=5,731) of patients having 3-month mRS scores available. In-hospital death, proportions of 3-month mRS scores 0–1 and mRS scores 0–2, and mortality did not exhibit significant trends before and after adjusting for age, sex, and initial NIHSS score. However, ordinal logistic regression revealed a significant increasing trend across the whole range of 3-month mRS scores after adjustments (common odds ratio, 1.18; 95% confidence interval, 1.04–1.33). The incidence of recurrent stroke displayed an increasing tendency, but this trend became insignificant after statistical adjustments.

Further analyses were conducted to identify factors contributing to the lack of improvement in outcomes despite improvement in treatments. The proportion of mRS scores 0–1 increased in patients who received MT and those with severe strokes (from 33.7% to 47.8% and from 13.2% to 25.0%, respectively; Tables S8 and S9). However, the proportion of mRS scores 0–2 and the mortality did not demonstrate significant improvements in these subgroups.

The one-year cumulative incidence of recurrent strokes slightly increased from 4.13% in 2011–2013 to 5.47% in 2017–2019 (p=0.041). However, this trend became non-significant after adjusting for sex, age, risk factors, and stroke subtypes. Interestingly, adjusting only for warfarin use resulted in the loss of statistical significance in the model. Figure 2 demonstrates the incidence of recurrent strokes according to the index stroke subtypes. The highest recurrence rate was observed in ODE. The increase in stroke recurrence rate in the last epoch

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

was attributable to the increased recurrence rate in CES, ODE, and UDE. Notably, in CES, patients who took warfarin had a lower recurrence rate than those who did not (Figure S1, p=0.14 on a log-rank test). In ODE, there was no difference in stroke recurrence between patients who took warfarin and those who did not (Figure S2).

Discussion

In our nationwide cohort of young adults with AIS, parameters regarding advanced treatments such as IVT and MT rates, DNT, and secondary preventive treatments, including DAPT for mild noncardioembolic stroke, DOAC for atrial fibrillation, and statin for LAA, improved over the 12 years. However, 3-month mRS score, 1-year mortality, and 1-year stroke recurrence rate did not improve. The stroke recurrence rate even increased in the last epoch, which was attributed to increased recurrence in patients with CES, ODE, or UDE.

Functional outcomes at 3 months after stroke did not improve and even worsened after adjusting for age, sex, and initial stroke severity in young adults with AIS. The proportion of mRS scores 0–2 was 84% in our study, similar to 84–94% in previous studies of young patients with ischemic stroke reported between the late 1990s and mid-2010s.[11,12,14] These studies were mostly cross-sectional; thus, further research is warranted to determine whether the stagnation or worsening of outcomes is a global trend or a local phenomenon.

On the other hand, functional outcomes seem to have improved during the last two decades in the general ischemic stroke population. Increased proportions of 3-month mRS scores 0–2 were reported in China (from 37% in 2002 to 71% in 2016) and Spain (from 49% in 2008 to 55% in 2016).[18,19] The Riks-Stroke registry and Get With The Guideline Stroke

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

data also demonstrated improving trends in discharge to home as a surrogate measure of functional outcome.[10,20]

The absence of improvement in functional outcomes between 2011–2013 and 2017–2019 despite improvement in delivery of treatments may be attributed to a ceiling effect, i.e., most young patients were already functionally independent in the early epoch (3-month mRS scores 0–2, 83.5% in 2011–2013). No improvement in the IVT rate (13.3% in 2011–2013 vs. 13.8% in 2017–2019) may be another explanation. The expansion of reperfusion therapy significantly contributes to improving outcomes in the general ischemic stroke population.[8,18–20] Although the MT rate has doubled, the number of beneficiaries was small, less than 10% of all AIS patients even in 2017–2019. In addition, the lack of improvement in ODT and DPT and the plateaued DNT might contribute to the stagnation of functional outcomes. The ODT, DNT, and DPT improved in the general stroke population of the United States.[21,22]

We demonstrated that the stroke recurrence rate was not reduced in young patients and even increased in the last epoch. This finding diverges from decreasing stroke recurrence in young adults with AIS in Sweden[15] and the general stroke population in the United States.[23] However, data about trends of stroke recurrence in the young stroke population since the late 2000s have not been reported in these countries.

To identify possible factors contributing to the increase in stroke recurrence in the last epoch, we examined changes in risk factors, stroke subtypes, and preventative treatments by epoch. During the 12-year observation period, we did not find notable changes except for the increase in ODE among ischemic stroke subtypes and the decrease in warfarin use (Tables 1, 2 and Table S5). When analyzing changes in stroke recurrence rates according to ischemic stroke subtypes, the increase in recurrence was seen in patients with CES, ODE, and

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

UDE (Figure 2). Interestingly, the decrease in warfarin use was most dramatic in the CES and ODE groups, with 21.1% and 27.5% reductions, respectively. Among patients with CES, the recurrence rate was higher in patients without warfarin use than in those with warfarin use (Figure S1). The decrease in warfarin use might be attributed to increased recurrent stroke in young adults with AIS. The increasing trend in the crude recurrence rate between 2011–2013 and 2017–2019 was no longer statistically significant after adjusting only for warfarin use, which supports this hypothesis.

Specific treatment guidelines in young stroke patients with CES and no atrial fibrillation, ODE, or UDE are not well-established.[24] In some patients with congenital or valvular heart disease, warfarin may be superior to antiplatelets or DOACs in preventing stroke recurrence by blocking several coagulation pathways simultaneously.[25] Further research is warranted to verify the recent increase in stroke recurrence in the young stroke population and the influence of warfarin use on this increase.

Awareness of and preventive treatments for traditional vascular risk factors are other important areas that require improvement. Only half of the study subjects with hypertension or diabetes had been on medication before the index stroke. Recent studies show that vascular risk factors in young adults are undertreated, partly because the widely used treatment thresholds of these risk factors underestimate the actual risk of stroke in young adults.[2]

Over the 12 years, the mean age of young patients with AIS decreased, which was attributed to an increase in the proportion of the youngest group (women, 18–30 years) (Figure 1B). A recent systematic review reported that the risk of stroke was higher in young women (15–35 years) than in young men.[26] However, despite the increasing trend in the proportion of women in our study, there were more men. A preponderance of young male stroke patients has been found in other studies from Asian countries.[27]

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

This study has several limitations. First, most participating hospitals are university hospitals or regional stroke centers, which might not represent acute stroke care hospitals in South Korea. However, our study's demographics and baseline characteristics are not different from those of a previous study based on national claims data[28], which covers 98–99% of the total Korean population. Second, we could not determine the causal relationship between treatments and outcomes due to the retrospective nature of data collection and the descriptive study design. Third, since we started to collect outcome data in 2011, we could only analyze the trends in outcomes during the last three epochs. Our findings of an increase in stroke recurrence in the last epoch could be play of chance; however, it may warrant subsequent study with a more extended observation period. Fourth, we do not have information on potential confounding risks such as migraine or use of oral contraceptives in this population. Fifth, our study was based on a nationwide stroke registry in South Korea. Therefore, the generalizability of our findings to other countries and ethnicities is limited.

In summary, clinical outcomes of young adults with AIS in South Korea did not improve between 2011 and 2019 despite increased delivery of AIS and recurrent preventive treatments. Early detection and treatment of traditional risk factors, expanded implementation and reduction of delay in reperfusion therapy, and establishment of optimal antithrombotic strategies in young patients with CES, ODE, and UDE are potential areas of improvement to close the clinical gap.

Sources of Funding:

This study was supported in part by the Korea Centers for Disease Control and Prevention (no. 2020ER620200f).

Disclosures: None.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Béjot Y, Daubail B, Jacquin A, Durier J, Osseby G-V, Rouaud O, Giroud M. Trends in the incidence of ischaemic stroke in young adults between 1985 and 2011: the Dijon Stroke Registry. *J Neurology Neurosurg Psychiatry*. 2014;85:509.

2. Scott CA, Li L, Rothwell PM. Diverging Temporal Trends in Stroke Incidence in Younger vs Older People. *Jama Neurol*. 2022;79.

3. Khan SU, Khan MZ, Khan MU, Khan MS, Mamas MA, Rashid M, Blankstein R, Virani SS, Johansen MC, Shapiro MD, et al. Clinical and Economic Burden of Stroke Among Young, Midlife, and Older Adults in the United States, 2002-2017. *Mayo Clin Proc Innovations Qual Outcomes*. 2021;

4. Goyal M, Menon BK, Zwam WH van, Dippel DWJ, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CBLM, Lugt A van der, Miquel MA de, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387:1723–1731.

5. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. *New Engl J Medicine*. 2008;359:1317–1329.

6. Pan Y, Elm JJ, Li H, Easton JD, Wang Y, Farrant M, Meng X, Kim AS, Zhao X, Meurer WJ, et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. *Jama Neurol*. 2019;76:1466–1473.

7. Chen A, Stecker E, Warden BA. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. *J Am Heart Assoc*. 2020;9:e017559.

8. Toyoda K, Yoshimura S, Nakai M, Koga M, Sasahara Y, Sonoda K, Kamiyama K, Yazawa Y, Kawada S, Sasaki M, et al. Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes. *Jama Neurol*. 2022;79:1–9.

9. Lee M, Wu Y-L, Ovbiagele B. Trends in Incident and Recurrent Rates of First-Ever Ischemic Stroke in Taiwan between 2000 and 2011. *J Stroke*. 2015;18:60–65.

10. Appelros P, Jonsson F, Åsberg S, Asplund K, Glader E-L, Åsberg KH, Norrving B, Stegmayr B, Terént A, Collaboration R-S. Trends in Stroke Treatment and Outcome between 1995 and 2010: Observations from Riks-Stroke, the Swedish Stroke Register. *Cerebrovasc Dis*. 2014;37:22–29.

11. Neau J-P, Ingrand P, Mouille-Brachet C, Rosier M-P, Couderq C, Alvarez A, Gil R. Functional Recovery and Social Outcome after Cerebral Infarction in Young Adults. *Cerebrovasc Dis*. 1998;8:296–302.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

12. Simonetti BG, Mono M-L, Huynh-Do U, Michel P, Odier C, Sztajzel R, Lyrer P, Engelter ST, Bonati L, Gensicke H, et al. Risk factors, aetiology and outcome of ischaemic stroke in young adults: the Swiss Young Stroke Study (SYSS). *J Neurol*. 2015;262:2025–2032.

13. Synhaeve NE, Arntz RM, Maaijwee NAM, Rutten-Jacobs LCA, Schoonderwaldt HC, Dorresteijn LDA, Kort PLM de, Dijk EJ van, Leeuw F-E de. Poor Long-Term Functional Outcome After Stroke Among Adults Aged 18 to 50 Years. *Stroke*. 2014;45:1157–1160.

14. Varona JF, Bermejo F, Guerra JM, Molina JA. Long-term prognosis of ischemic stroke in young adults. *J Neurol*. 2004;251:1507–1514.

15. Giang KW, Björck L, Ståhl CH, Nielsen S, Sandström TZ, Jern C, Torén K, Rosengren A. Trends in risk of recurrence after the first ischemic stroke in adults younger than 55 years of age in Sweden. *Int J Stroke*. 2015;11:52–61.

16. Bae H-J, Kim JY, Kang J, Kim BJ, Han M-K, Choi K-H, Kim J-T, Park M-S, Cho K-H, Kim BK, et al. David G. Sherman Lecture Award: 15-Year Experience of the Nationwide Multicenter Stroke Registry in Korea. *Stroke*. 2022;101161STROKEAHA122039212.

17. Ko Y, Lee S, Chung J-W, Han M-K, Park J-M, Kang K, Park TH, Park S-S, Cho Y-J, Hong K-S, et al. MRI-based Algorithm for Acute Ischemic Stroke Subtype Classification. *J Stroke*. 2014;16:161–172.

18. Rodríguez-Castro E, López-Dequit I, Santamaría-Cadavid M, Arias-Rivas S, Rodríguez-Yáñez M, Pumar JM, Hervella P, López-Arias E, Silva-Candal A da, Estany A, et al. Trends in stroke outcomes in the last ten years in a European tertiary hospital. *Bmc Neurol*. 2018;18:164.

19. Liu J, Zheng L, Cheng Y, Zhang S, Wu B, Wang D, Zhang S, Tao W, Wu S, Liu M. Trends in Outcomes of Patients With Ischemic Stroke Treated Between 2002 and 2016. *Circulation Cardiovasc Qual Outcomes*. 2019;12:e005610.

20. Song S, Fonarow GC, Olson DM, Liang L, Schulte PJ, Hernandez AF, Peterson ED, Reeves MJ, Smith EE, Schwamm LH, et al. Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke. *Stroke*. 2018;47:1294–1302.

21. Menon BK, Xu H, Cox M, Saver JL, Goyal M, Peterson E, Xian Y, Matsuoka R, Jehan R, Yavagal D, et al. Components and Trends in Door to Treatment Times for Endovascular Therapy in Get With The Guidelines-Stroke Hospitals. *Circulation*. 2019;139:169–179.

22. Xian Y, Xu H, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Hernandez AF, Peterson ED, Schwamm LH, Fonarow GC. Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention. *Stroke*. 2022;53:1328–1338.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

23. Sozener CB, Lisabeth LD, Shafie-Khorassani F, Kim S, Zahuranec DB, Brown DL, Skolarus LE, Burke JF, Kerber KA, Meurer WJ, et al. Trends in Stroke Recurrence in Mexican Americans and Non-Hispanic Whites. *Stroke*. 2020;51:2428–2434.

24. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2019;50:e344–e418.

25. Bhatt AB, Foster E, Kuehl K, Alpert J, Brabeck S, Crumb S, Davidson WR, Earing MG, Ghoshhajra BB, Karamlou T, et al. Congenital Heart Disease in the Older Adult. *Circulation*. 2015;131:1884–1931.

26. Leppert MH, Burke JF, Lisabeth LD, Madsen TE, Kleindorfer DO, Sillau S, Schwamm LH, Daugherty SL, Bradley CJ, Ho PM, et al. Systematic Review of Sex Differences in Ischemic Strokes Among Young Adults: Are Young Women Disproportionately at Risk? *Stroke*. 53:319–327.

27. Jacob MA, Ekker MS, Allach Y, Cai M, Aarnio K, Arauz A, Arnold M, Bae H-J, Bandeo L, Barboza MA, et al. Global Differences in Risk Factors, Etiology, and Outcome of Ischemic Stroke in Young Adults—A Worldwide Meta-analysis. *Neurology*. 2022;98:e573–e588.

28. Kim JY, Kang K, Kang J, Koo J, Kim D-H, Kim BJ, Kim W-J, Kim E-G, Kim JG, Kim J-M, et al. Executive Summary of Stroke Statistics in Korea 2018: A Report from the Epidemiology Research Council of the Korean Stroke Society. *J Stroke*. 2018;21:42–59.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Tables

Table 1 Secular Trends in Demographics, Risk Factors, and Subtypes of Ischemic Stroke

Variables		2008–2010 (n=993)	2011–2013 (n=1753)	2014–2016 (n=2055)	2017–2019 (n=2249)	*p* for trend*
Men		73.7%	72.4%	71.0%	71.3%	0.10
Mean age (SD), years	All	43.6 (6.1)	43.2 (6.6)	43.1 (6.4)	42.9 (6.9)	0.009
	Men	43.7 (5.9)	43.5 (6.4)	43.3 (6.3)	43.3 (6.4)	0.14
	Women	43.5 (6.6)	42.3 (7.0)	42.6 (6.8)	42.0 (7.8)	0.02
Risk factors						
Current smoking	All	53.1%	50.5%	47.6%	42.8%	<0.001
	Men	68.2%	65.3%	62.5%	54.7%	<0.001
	Women	10.7%	11.8%	10.9%	13.2%	0.32
Obesity (BMI ≥30 kg/m^2)	All	5.2%	7.2%	10.5%	12.0%	<0.001
	Men	5.2%	7.1%	10.6%	13.1%	<0.001
	Women	5.4%	7.7%	10.1%	9.2%	0.053
Hypertension	All	43.2%	43.7%	40.6%	43.4%	0.77
	Men	47.0%	46.9%	43.9%	47.4%	0.99
	Women	32.6%	35.2%	32.4%	33.3%	0.83
Aware†		81.4%	76.9%	80.8%	78.4%	0.69
On medication‡		60.7%	63.7%	54.6%	63.7%	0.85
Diabetes mellitus	All	20.8%	20.0%	19.8%	20.9%	0.81
	Men	22.1%	20.7%	21.4%	22.4%	0.56
	Women	17.2%	18.2%	16.0%	17.1%	0.70
Aware†		72.9%	74.6%	74.4%	73.2%	0.91
On medication‡		72.8%	72.5%	68.3%	72.1%	0.73
Hyperlipidemia	All	25.2%	28.8%	25.9%	27.0%	0.91
	Men	26.6%	31.5%	28.6%	30.0%	0.48
	Women	21.1%	21.5%	19.2%	19.7%	0.43
Aware†		35.6%	38.9%	48.1%	51.3%	<0.001
On medication‡		60.7%	62.8%	53.1%	64.1%	0.66
Atrial fibrillation	All	6.0%	5.0%	4.9%	4.3%	0.04
	Men	5.2%	4.3%	5.2%	4.3%	0.61
	Women	8.4%	6.8%	4.0%	4.2%	0.003
Aware†		61.7%	47.1%	50.0%	42.7%	0.0496
On medication‡		32.4%	34.2%	40.0%	43.9%	0.24
Ischemic stroke subtypes						
Large artery atherosclerosis	All	30.8%	33.5%	30.4%	28.3%	0.008
	Men	32.5%	35.0%	31.6%	30.0%	0.03
	Women	26.1%	29.6%	27.4%	24.0%	0.17
Small vessel occlusion	All	26.8%	22.9%	22.1%	21.7%	0.004
	Men	28.3%	25.2%	24.2%	22.9%	0.01
	Women	22.6%	16.8%	16.8%	18.8%	0.48
Cardioembolic stroke	All	14.0%	11.0%	11.2%	9.7%	0.001
	Men	12.8%	9.3%	10.4%	9.2%	0.05
	Women	17.2%	15.5%	13.3%	10.9%	0.01
Other determined etiology	All	8.6%	10.4%	12.9%	17.6%	<0.001

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

	Men	7.9%	9.4%	10.4%	16.0%	<0.001
	Women	10.3%	13.0%	19.2%	21.6%	<0.001
Undetermined etiology	All	19.8%	22.3%	23.4%	22.6%	0.11
	Men	18.5%	21.1%	23.2%	21.9%	0.07
	Women	23.7%	25.1%	23.3%	24.8%	0.90

Values are percentages unless indicated otherwise.

* *p* for trend by Cochran-Armitage trend test for categorical and by ANOVA linear contrast test for continuous variables.

† Proportion of preexisting risk factors among all patients diagnosed with the risk factor during index stroke admission.

‡ Proportion of patients who had been prescribed medicine for the risk factor among those diagnosed with the risk factor before index stroke.

BMI, body mass index.

Table 2 Secular Trends in Clinical Presentation and Treatments

Variables	2008–2010 (n=993)	2011–2013 (n=1753)	2014–2016 (n=2055)	2017–2019 (n=2249)	*p* for trend*
Onset-to-door time					
Median FAT-to-door (IQR), h	8.4 (1.9–29.5)	8.2 (2.4–33.5)	9.4 (2.1–33.6)	8.0 (2.0–31.6)	0.66
Median LKW-to-door (IQR), h	11.7 (2.8–32.7)	11.1 (3.0–37.1)	12.5 (3.1–38.7)	11.4 (2.8–34.6)	0.62
LKW-to-door within 3.5h	27.7%	27.8%	26.5%	28.1%	0.92
Stroke severity					
Mean initial NIHSS score (SD)	4.8±5.5	4.2±5.3	4.2±5.1	4.0±4.9	<0.001
Median initial NIHSS score (IQR)	3 (1–6)	2 (1–5)	2 (1–5)	2 (1–5)	<0.001
Mild stroke (≤4)	64.9%	71.0%	70.7%	69.8%	0.06
Moderate stroke (5–15)	28.3%	23.4%	24.0%	25.3%	0.39
Severe stroke (16–42)	6.8%	5.6%	5.4%	4.9%	0.03
Reperfusion therapy					
IVT rate	9.5%	13.3%	14.0%	13.8%	0.004
Median DNT (IQR), min	58 (43–83)	40 (31–54)	37 (26.8–49)	39 (29–55.8)	<0.001
DNT ≤60 min	56.2%	84.2%	86.3%	81.5%	<0.001
MT rate	3.2%	5.3%	7.5%	9.2%	<0.001
Median DPT (IQR), min	113 (88–146)	110 (92–137)	115.5 (87.3–158.5)	106 (85–153.3)	0.84
DPT ≤90 min	26.1%	23.5%	31.2%	30.9%	0.28
Discharge medications					
Dual antiplatelet therapy	26.7%	24.8%	32.8%	47.0%	<0.001
In noncardioembolic minor stroke	28.6%	25.0%	35.2%	50.8%	<0.001
Anticoagulation	15.8%	13.1%	9.6%	8.6%	<0.001
Warfarin	15.2%	11.6%	6.8%	4.3%	<0.001
DOAC	0.0%	0.2%	2.3%	3.8%	<0.001
Anticoagulation in AF	78.3%	78.2%	71.0%	71.9%	0.22
Warfarin in AF	75.0%	72.4%	41.0%	14.6%	<0.001
DOAC in AF	0.0%	4.6%	30.0%	56.2%	<0.001
Statin	71.5%	79.9%	86.9%	91.2%	<0.001
Among LAA	76.1%	86.2%	89.8%	95.3%	<0.001

Values are percentages unless indicated otherwise.

* *p* for trend by Cochran–Armitage trend test for categorical and ANOVA linear contrast test for continuous variables.

AF, atrial fibrillation; DNT, door-to-needle time; DOAC, direct oral anticoagulant; DPT, door-to-puncture time; FAT, first abnormal time; IVT, intravenous thrombolysis; LAA, large artery atherosclerosis; LKW, last known well time; MT, mechanical thrombectomy; National Institute of Health Stroke Scale.

Table 3 Secular Trends in Clinical Outcomes of Ischemic Stroke

Variables	2011–2013 (n=1753)	2014–2016 (n=2055)	2017–2019 (n=2249)	Unadjusted *p* for trend*	Adjusted *p* for trend†
In-hospital death	0.90%	1.50%	1.00%	0.71	0.23‡
3-month mRS score				0.16	**0.007**
0	39.9%	37.1%	35.9%		
1	27.3%	30.7%	32.7%		
2	16.3%	16.4%	14.5%		
3	8.5%	8.1%	8.7%		
4	4.0%	3.9%	4.1%		
5	2.0%	1.5%	2.0%		
6	2.0%	2.3%	2.2%		
Mean (SD)	2.23 (1.42)	2.25 (1.40)	2.27 (1.42)		
Median (IQR)	2 (1–3)	2 (1–3)	2 (1–3)		
3-month mRS scores 0–1	67.2%	67.8%	68.6%	0.37	0.63‡
3-month mRS scores 0–2	83.5%	84.2%	83.0%	0.64	0.22‡
Mortality				0.50	0.83‡
30 days	1.59 (0.99–2.18)	1.83 (1.25–2.41)	1.44 (0.94–1.93)		
90 days	1.95 (1.29–2.61)	2.13 (1.50–2.76)	1.89 (1.33–2.46)		
365 days	2.52 (1.77–3.28)	2.93 (2.19–3.68)	2.32 (1.69–2.95)		
Cumulative incidence of recurrent strokes				0.04	0.22**
30 days	2.00 (1.33–2.66)	1.59 (1.04–2.14)	2.53 (1.88–3.19)		
90 days	3.34 (2.48–4.21)	2.16 (1.52–2.79)	4.11 (3.28–4.94)		
365 days	4.13 (3.17–5.09)	3.70 (2.86–4.55)	5.47 (4.51–6.44)		

* Unadjusted *p*-values by Mantel–Haenszel chi-square test for 3-month mRS scores, Cochran–Armitage trend test for categorical, ANOVA linear contrast test for continuous variables, and log-rank linear contrast test for survival outcomes.

†Adjusted *p*-values by ordinal logistic regression for 3-month mRS score, linear contrast test of logistic regression models for in-hospital death, 3-month mRS scores 0–1 and 0–2, and linear contrast test for Cox proportional hazard models for mortality and recurrent stroke.

‡ In-hospital death, 1-year mortality, and 3-month mRS score were adjusted for sex, age, and initial NIHSS score.

** The cumulative incidence of recurrent strokes was adjusted for sex, age, risk factors, and stroke subtypes.

mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Scale.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure Legends

Figure 1 Trends in Mean Age Between 2008 and 2019

(A) Mean age according to sex and calendar year, (B) secular changes in proportions of age groups in women, and (C) secular changes in proportions of age groups in men.

Figure 2 Stroke Recurrence According to Epochs and Stroke Subtypes

Stroke recurrence in (A) overall, (B) large artery atherosclerosis, (C) small vessel occlusion, (D) cardioembolic stroke, (E) other determined etiology, and (F) undetermined etiology.







medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2023.04.17.23288712; version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .